Upregulating MicroRNA-410 or Downregulating Wnt-11 Increases Osteoblasts and Reduces Osteoclasts to Alleviate

Yukun Yin1, Lixiang Ding2, Yu Hou3

  • 1Department of Traditional Chinese Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Nanoscale Research Letters
|December 20, 2019
PubMed
Abstract

Insights

Upregulating microRNA-410 (miR-410) or downregulating Wnt-11 promotes osteoblasts and reduces osteoclasts, potentially preventing osteonecrosis of the femoral head (ONFH). This suggests miR-410 as a therapeutic target for ONFH.

Area of Science:

  • Biomedical research
  • Molecular biology
  • Orthopedics

Background:

  • Osteonecrosis of the femoral head (ONFH) pathogenesis remains incompletely understood.
  • The specific role of microRNA-410 (miR-410) in ONFH is largely unknown.
  • Investigating miR-410's interaction with Wnt-11 is crucial for understanding ONFH mechanisms.

Purpose of the Study:

  • To elucidate the functional role of miR-410 in ONFH.
  • To investigate the targeting of Wnt-11 by miR-410.
  • To modulate osteogenic and osteoclastic pathways for ONFH prevention.

Main Methods:

  • Comparative analysis of ONFH and normal femoral head tissues.
  • In vivo study using a rat model of ONFH treated with miR-410 agomir or Wnt-11 siRNA/oe.
  • Quantitative assessment of osteogenic markers (ALP, BGLAP, Collα1) and osteoclastic markers (ACP5, CTSK, MMP9) via RT-qPCR, Western blot, and ELISA.

Main Results:

  • ONFH tissues showed decreased miR-410, ALP, BGLAP, and Collα1, with increased Wnt-11, ACP5, CTSK, and MMP9.
  • miR-410 upregulation and Wnt-11 downregulation in rats improved bone mineral density and bone structure.
  • Treatment modulated osteogenic and osteoclastic markers, suppressed osteocyte apoptosis, and improved serum calcium and phosphorus levels.

Conclusions:

  • Upregulating miR-410 or downregulating Wnt-11 promotes osteoblast activity and inhibits osteoclast activity.
  • These modulations alleviate ONFH progression.
  • miR-410 presents a promising therapeutic target for ONFH treatment.